+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Naloxone Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

  • ID: 5317902
  • Report
  • March 2021
  • Region: Global
  • 105 pages
  • Acute Market Reports

FEATURED COMPANIES

  • Adapt Pharma Inc.
  • Hospira (Pfizer Inc.)
  • Kaleo Inc.
  • Mylan N.V.
Industry Outlook

The global naloxone market held US$ 3,359.5 Mn in 2020 and expected to grow at compound annual growth rate (CAGR) of 9.7% during the forecast period from 2021 to 2029. Naloxone is an opioid antagonist designed to rapidly reverse opioid overdose. Naloxone is able to restore normal respiration of a person whose breathing has stopped or slowed down due to opioid or heroin overdose. Currently, opioid abuse is one of the foremost cause of drug overdose and leading cause of death globally. However, it is more common in North America and Europe. The problem is paramount in the United States, where the mortality due to opioid overdose surged by 21% in 2016. The opioid crises in the U.S. is has reached epidemic phase, causing serious healthcare costs and losses to resources. The excessive need for better treatment and people suffering from opioid dependence is resulting in the growth in naloxone market in the United States. Opioid dependence is a serious concern globally, with more than 25 million people affected. The problem exists in both developed as well as developing countries, but is greatest in the Unites States. Heroin is the most abused opioid in the world apart from U.S. where opioid prescription painkillers are the largely consumed leading to dependency and overdose. All these factors act as a drivers of the global naloxone market. However, overall the price of Naloxone is rising and acting as a barrier to reduce the number of deaths caused due to opioid overdose. In the United States the effect of sky rocketing prices is being reduced with supportive insurance plans and free sale of Naloxone through community based organizations or public health programs.

Rising Awareness Related to Opioid Overdose and its Effective Treatment in Developed as well as Developing Countries

According to Penington Institute, globally an estimate of 0.19 million premature deaths caused by drugs, of which opioids account for the maximum share of drug-related deaths and that are avoidable in most cases. In January 2017, the Centre for Disease Control and Prevention (CDC) estimated that 64,070 people dies of overdoses in the 12 month period between 2016 and 2017. Thus, these statistics exhibit a clear picture of effect of opioid over dose across the globe. Government and non-government agencies across the developed and developing countries are introducing awareness campaigns to educate people about the overdose of Naloxone and treatment options. For example, Good Samaritan laws is established in the 40 states in the U.S. providing protection for people reporting overdoses in good faith. The scope of offenses are protected by immunity provision that differ state wise.

North America Dominated the Global Naloxone Market

In 2020, North America held the largest share in the global naloxone market owing wide presence of pharmaceutical giants, huge manufacturing base and favorable government initiative to curb opioid overdose crises in the region. U.S. is the leading market for Naloxone due to sharp increase in the prescription painkillers resulting in the over 10 million high-risk opioid users in the U.S. It is estimated that half this population have developed dependence and only 16% are undergoing treatment. Increasing government campaigns regarding knowledge and awareness of opioid dependence and risks have further driven the market for naloxone. Efficient reimbursement scenario and subsidized rate of the medication due to The Affordable Care Act has led to the heightened demand for naloxone. Europe emerged as the fastest growing region due to growing cases of opioid dependence, awareness and greater access to treatment.

Historical & Forecast Period

This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2021 to 2029.

Market is studied in order to understand the current dynamics and future trends in the global naloxone market. The study includes market size and forecast for all considered segments presented in the report for the period from 2021 to 2029, along with respective compound annual growth rate (CAGRs) for the forecast period from 2021 to 2029, considering 2017 as the base year. The key players currently engaged in naloxone market include Hospira (Pfizer, Inc.), Mylan N.V., Kaleo, Inc., Amphastar Pharmaceuticals, Inc., Adapt Pharma, Inc., Mundipharma International Limited among others. The market players are engaged in receiving marketing authorization in North America and Europe owing greater target population. In 2020, Mylan N.V. launched naloxone hydrochloride injection in the U.S.; while Mundipharma received European Medicines Approval (EMA) for intranasal naloxone in 2017. Number of generic manufacturers are operating in the market and account for a significant share in the naloxone market.

Key questions answered in this report
  • How the global naloxone market will perform during the forecast period from 2020 to 2029?
  • What are the latest trends in the naloxone market and valuable opportunities for key players?
  • Who are the leading players in the global naloxone market?
  • Which is the leading/and fastest region in the global naloxone market?
  • What are drivers and restrains governing the global naloxone market?
  • What are regulatory scenario for naloxone in North America, Europe and Rest of the World?
  • What is the epidemiology of opioid dependence and risk associated with it to society?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adapt Pharma Inc.
  • Hospira (Pfizer Inc.)
  • Kaleo Inc.
  • Mylan N.V.
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Naloxone Market Portraiture
2.2. Global Naloxone Market, by Formulation, 2020 (US$ Mn)
2.3. Global Naloxone Market, by Dosage, 2020 (US$ Mn)
2.4. Global Naloxone Market, by Sales Channel, 2020 (US$ Mn)
2.5. Global Naloxone Market, by Geography, 2020 (US$ Mn)

Chapter 3. Global Naloxone: Market Dynamics and Outlook
3.1. Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2020
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2020

Chapter 4. Global Naloxone Market, by Formulation, 2019 – 2029 (US$ Mn)
4.1. Overview
4.2. Parenteral
4.2.1. Evzio
4.2.2. Generic Drugs
4.3. Intranasal
4.3.1. NARCAN
4.4. Sublingual
4.4.1. Zubsolv
4.4.2. Suboxone
4.4.3. Generic Drugs

Chapter 5. Global Naloxone Market, by Dosage, 2019 – 2029 (US$ Mn)
5.1. Overview
5.2. 4mg/0.1 ml
5.3. 2mg/0.1 ml
5.4. 0.4 mg/0.4 ml
5.5. 2mg/0.4 ml
5.6. Others (1mg/ml, 0.4 mg/ml, 4mg/10ml)

Chapter 6. Global Naloxone Market, by Sales Channel, 2019 – 2029 (US$ Mn)
6.1. Overview
6.2. Hospitals Pharmacy
6.3. Outpatient Retail Pharmacy
6.4. Online Pharmacy
6.5. Wholesaler

Chapter 7. Global Naloxone Market, by Geography, 2019 – 2029 (US$ Mn)
7.1. Overview
7.2. North America
7.2.1. North America Naloxone Market, by Formulation, 2019 – 2029 (US$ Mn)
7.2.2. North America Naloxone Market, by Dosage, 2019 – 2029 (US$ Mn
7.2.3. North America Naloxone Market, by Sales Channel, 2019 – 2029 (US$ Mn)
7.2.4. North America Naloxone Market, by Country, 2019 – 2029 (US$ Mn)
7.2.4.1. U.S.
7.2.4.2. Canada
7.3. Europe
7.3.1. Europe Naloxone Market, by Formulation, 2019 – 2029 (US$ Mn)
7.3.2. Europe Naloxone Market, by Dosage, 2019 – 2029 (US$ Mn
7.3.3. Europe Naloxone Market, by Sales Channel, 2019 – 2029 (US$ Mn)
7.3.4. Europe Naloxone Market, by Country, 2019 – 2029 (US$ Mn)
7.3.4.1. U.K
7.3.4.2. Germany
7.3.4.3. Rest of Europe
7.4. Asia Pacific
7.4.1. Asia Pacific Naloxone Market, by Formulation, 2019 – 2029 (US$ Mn)
7.4.2. Asia Pacific Naloxone Market, by Dosage, 2019 – 2029 (US$ Mn
7.4.3. Asia Pacific Naloxone Market, by Sales Channel, 2019 – 2029 (US$ Mn)
7.4.4. Asia Pacific Naloxone Market, by Country, 2019 – 2029 (US$ Mn)
7.4.4.1. Japan
7.4.4.2. China
7.4.4.3. Rest of APAC
7.5. Latin America
7.5.1. Latin America Naloxone Market, by Formulation, 2019 – 2029 (US$ Mn)
7.5.2. Latin America Naloxone Market, by Dosage, 2019 – 2029 (US$ Mn
7.5.3. Latin America Naloxone Market, by Sales Channel, 2019 – 2029 (US$ Mn)
7.5.4. Latin America Naloxone Market, by Country, 2019 – 2029 (US$ Mn)
7.5.4.1. Brazil
7.5.4.2. Mexico
7.5.4.3. Rest of LATAM
7.6. Middle East & Africa
7.6.1. Middle East & Africa Naloxone Market, by Formulation, 2019 – 2029 (US$ Mn)
7.6.2. Middle East & Africa Naloxone Market, by Dosage, 2019 – 2029 (US$ Mn
7.6.3. Middle East & Africa Naloxone Market, by Sales Channel, 2019 – 2029 (US$ Mn)
7.6.4. Middle East & Africa Naloxone Market, by Country, 2019 – 2029 (US$ Mn)
7.6.4.1. GCC
7.6.4.2. Rest of MEA

Chapter 8. Profiles
8.1. Mylan N.V.
8.1.1. Business Description
8.1.2. Financial Information (Subject to Data Availability)
8.1.3. Product Portfolio
8.1.4. Key Developments
8.2. Indivior Plc.
8.3. Sandoz (Novartis AG)
8.4. Adapt Pharma, Inc.
8.5. Amphastar Pharmaceuticals, Inc.
8.6. INSYS Therapeutics, Inc.
8.7. Mundipharma International Limited
8.8. Kaleo, Inc.
8.9. Orexo AB
8.10. Kern Pharma, S.L.
8.11. Hospira (Pfizer, Inc.)
8.12. UCB Pharma
Note:
Modification in the list of company profiles or scope of the study can be incorporated on request.
Note: Product cover images may vary from those shown
  • Hospira (Pfizer Inc.)
  • Mylan N.V.
  • Kaleo Inc.
  • Amphastar Pharmaceuticals Inc.
  • Adapt Pharma Inc.
  • Mundipharma International Limited
Note: Product cover images may vary from those shown
Adroll
adroll